Precision Medicine May Benefit Patients with Rare Tumors
In a recent study, more than half of patients with rare cancers who had their genomic markers analyzed were able to receive targeted therapy that resulted in a clinical benefit.
Repurposed Poziotinib Offers New Hope for Some NSCLC Patients
Poizotinib, once abandoned as a general EGFR inhibitor, recently demonstrated tumor shrinkage in patients with an EGFR exon 20 insertion mutation.
Poliovirus Therapy May Provide a Double Attack on Cancer
An investigational therapy using modified poliovirus to attack cancer appears to unleash the body’s own capacity to fight malignancies by activating a newly identified inflammatory process.
Androgen Receptor Linked to Different Metastases in RCC
Researchers have discovered that androgen signaling can either stimulate or suppress tumor cell movement and invasion to different locations in the body in patients who have renal cell carcinoma.
Venetoclax in the Context of the Current CLL Treatment Paradigm
In this podcast interview, Dr. William Wierda discusses the role of venetoclax in treating patients with chronic lymphocytic leukemia, particularly in light of recent trial results.
Alectinib Approved as First-Line Therapy for ALK-Positive Metastatic NSCLC
The FDA approved alectinib as first-line therapy for ALK-positive non-small cell lung cancer based on results of the ALEX study, which showed significant improved PFS compared with crizotinib.
EZH2 Protein May be a Prognostic Marker for Localized Clear Cell RCC
Data from three independent cohorts suggest that high EZH2 expression may mean a higher risk of death for patients with clear cell renal cell carcinoma.
A New Method of Combating MAPK Inhibitor-Resistant Melanoma
Researchers have found that melanoma patients may benefit from a holiday from MAPK inhibitors while alternative therapies stave off emergence of resistant melanoma clones.
Pembrolizumab Demonstrates Increased Overall Survival in Metastatic NSCLC Patients
Data presented at the recent World Conference on Lung Cancer show that pembrolizumab improves overall survival in patients with metastatic non-small cell lung cancer whose tumors express high levels of PD-L1.
Tumor Infiltrating Lymphocytes May be Predictive in African-American Women with Triple-Negative Breast Cancer
For African-American women with triple-negative breast cancer, high levels of tumor infiltrating lymphocytes may mean a better prognosis.
Combating Breast Cancer Bone Metastases with Docetaxel-Encapsulated Nanotherapy
Researchers have developed nanoparticles that can carry targeted therapy to tumors with bone metastases, which may have particular benefit for breast cancer patients.
Radiation plus Immunotherapy May Benefit Some Patients with Metastatic NSCLC
Data presented at the ASTRO annual meeting demonstrate a benefit of radiation plus immunotherapy for patients with advanced disease, including stage IV NSCLC.
Immunotherapy and Hyperprogression of Disease
Drs. Kurzrock and Kato discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
New Guidelines Proposed for Preventing and Treating CAR T-Cell Side Effects
A team of investigators from multiple institutions has proposed new guidelines for monitoring, grading, and managing the side effects of CAR T-cell therapy.
Link Between Fanconi Anemia Genetic Mutations and Cancer Risk
Researchers have discovered that genetic mutations associated with Fanconi Anemia may also result in a higher risk for certain cancers, even in patients who don't exhibit symptoms of the disease.